Loxapine: the inhaled and oral antipsychotic

Loxapine sits in an interesting spot in the antipsychotic landscape. Chemically it is a dibenzoxazepine — structurally related to clozapine — and was FDA-approved in 1975 as a first-generation antipsychotic. In 2012 the FDA approved a second formulation: an inhaled powder called Adasuve for the acute treatment of agitation in adults with schizophrenia or bipolar I disorder. That dual identity makes loxapine genuinely unusual.

The pharmacology

Loxapine blocks dopamine D2 receptors and serotonin 5-HT2A receptors with a profile that some clinicians describe as feeling "in between" first- and second-generation drugs. Its active metabolite, amoxapine, has additional antidepressant activity. The receptor profile gives loxapine somewhat better tolerability for some patients than the highest-potency typicals — though it is still classified as a first-generation antipsychotic.

The oral form

Oral loxapine is used for the long-term treatment of schizophrenia at doses typically in the 20–100 mg/day range, divided into 2–4 doses. Onset of action is similar to other oral antipsychotics — calming effects within days, full antipsychotic effect over weeks. Common side effects include sedation, EPS (less than haloperidol but more than clozapine), modest weight gain, anticholinergic effects, and prolactin elevation. The Adasuve label and oral loxapine prescribing information detail the full profile.

The inhaled form (Adasuve)

Adasuve is delivered through a single-use, breath-actuated inhaler. The patient takes one deep inhalation, and loxapine is rapidly absorbed across the lung surface — peak plasma levels occur within about 2 minutes. This makes it one of the fastest-acting antipsychotics available, comparable in onset to intramuscular injections but without a needle.

Adasuve is approved for one inhalation per 24-hour period. It is used in emergency departments, inpatient units, and other supervised settings for patients with acute agitation who can cooperate with the inhaler. It is not used for daily maintenance treatment.

The bronchospasm warning

Pre-treatment screening includes asking about asthma, COPD, and other airway disease, and listening to the chest. Patients with active bronchospasm cannot receive Adasuve.

How effective is the inhaled form?

The pivotal trials of inhaled loxapine showed significant reduction in agitation scores within 10 minutes of administration, sustained for at least 2 hours. Compared with intramuscular injections, the inhaled form offers similar speed without the needle — which can be important for patients with needle phobia, trauma histories, or capacity for cooperation.

Common side effects

• Sedation — common with both oral and inhaled forms
• EPS — moderate; akathisia, parkinsonism, occasional dystonia
• Anticholinergic effects — dry mouth, constipation, blurred vision
• Orthostatic hypotension — particularly during oral titration
• Hyperprolactinemia — like other D2 blockers
• Throat irritation or cough — specific to the inhaled form
• Mild taste changes with Adasuve

Less common but serious effects

• Bronchospasm — Adasuve only; immediate albuterol if it occurs
• Tardive dyskinesia — long-term oral use
• Neuroleptic malignant syndrome — rare
• Lowered seizure threshold — modest
• QT prolongation — modest

Who oral loxapine fits

• People who responded to it historically
• People who want a first-generation drug with somewhat better tolerability than the highest-potency typicals
• Cost-sensitive prescribing

Who Adasuve fits

• Patients in supervised settings with acute agitation
• Patients without significant respiratory disease
• Patients who can cooperate with using the inhaler
• Patients who prefer a non-injection rescue option when one is medically appropriate

Practical questions to ask

• For oral loxapine: what dose are we aiming for, and how will we monitor for movement side effects?
• For Adasuve: do I have any breathing conditions that would make me ineligible?
• How does this compare with other agitation rescue options like IM olanzapine, IM ziprasidone, or IM haloperidol-with-lorazepam?

The big picture

Loxapine has not been a high-volume drug for decades, but its inhaled formulation has carved out a small, useful role in modern crisis psychiatry. For everyday treatment of schizophrenia, it remains an option — neither obviously better nor obviously worse than other first-generation drugs, with a profile that some patients find more tolerable than haloperidol or fluphenazine. As always, the question is how it fits your particular situation, and that is a conversation with your prescriber.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.